Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

New Glucose-regulating Protein Linked With Diabetes Discovered By UCSF
Researchers at the University of California, San Francisco, and collaborators at Harvard Medical School have linked a specialized protein in human muscles to the process that clears glucose out of the bloodstream, shedding light on what goes wrong in type 2 diabetes on a cellular level.
pharmacy online
Will Individuals With Alzheimer's Disease Benefit From Cataract Surgery?
A multi-institutional team of researchers, led by the Mandel School of Applied Social Sciences at Case Western Reserve University, will begin a five-year, $2.9 million National Institutes of Health-funded study. They will examine the lives of patients with both cataracts and Alzheimer"s disease (AD) to document how restored vision improves everyday life for people with dementia.
News of the day
ActoGeniX Obtains IND Approval
ActoGeniX, a development stage biopharmaceutical company, announced that the United States÷´ Food and Drug Administration (FDA) has approved the Company÷´s Investigational New Drug (IND) application for AG013, a novel therapeutic product for the treatment of oral mucositis in cancer patients. This IND application approval allows ActoGeniX to initiate a phase 1B clinical trial with AG013, which will now become the second clinical development program in ActoGeniX÷´s portfolio.
Oncology

MDRNA, Inc. Receives Full FDA Approval Of Generic Calcitonin-Salmon Nasal Spray For Osteoporosis

MDRNA, Inc. (NASDAQ: MRNA) announced that it has obtained full U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray for the treatment of osteoporosis and that Par Pharmaceutical Companies, Inc. (NYSE: PAR) has launched the product. Calcitonin-salmon nasal spray, a legacy product developed by MDRNA in the early 2000s, is the generic equivalent of Miacalcin® nasal spray, marketed by Novartis Pharmaceuticals Corporation. U.S. sales of Miacalcin® were approximately $112 million in 2008, according to IMS Health data. On March 31, 2009, MDRNA and Par entered into an agreement under which Par acquired the Company"s Abbreviated New Drug Application (ANDA) for generic calcitonin-salmon nasal spray and the Company"s FDA-approved, cGMP manufacturing facility in Hauppauge, New York, for an upfront cash payment and profit sharing on commercial sales for five years. "We are pleased that generic calcitonin-salmon nasal spray has received full FDA approval and has been launched by Par," stated J. Michael French, President and CEO of MDRNA. "Revenue generated from the sale of calcitonin-salmon by Par will provide us with working capital to help advance our RNAi programs. I thank the team at MDRNA and Par for their superb efforts to bring this product to market." For additional product information, please visit http://www.parpharm.com/products. MDRNA, Inc.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009